Report the Phase 3 Clarity AD confirmatory study readout for lecanemab
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 3 May 2022
- Due
- 30 Nov 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the readout of the Phase 3 Clarity AD confirmatory study for lecanemab is expected in the fall of 2022.”
What we found
Evidence strength A What the grades mean
The 10-K filed 2023-02-15 reports positive topline results from the confirmatory Phase 3 CLARITY study in September 2022, within the fall 2022 window.
-
A Biogen 10-K filed 2023-02-15
“In September 2022 we and Eisai announced positive topline results from the confirmatory Phase 3 CLARITY Alzheimer's disease study of LEQEMBI.” ✓ confirmed on the page
-
A Biogen 10-K filed 2023-02-15
“LEQEMBI met the primary endpoint and all key secondary endpoints with highly statistically significant results.” ✓ confirmed on the page
Market reaction: the shares moved -2.4% against the S&P 500 over the three sessions around the disclosure (14 Feb 2023 to 17 Feb 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Phase 3 Clarity AD study readout
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
- Depends on
- Partner
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Biogen? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-BIIB-005346 · Corrections policy